Skip to content

Study · Not a test of the peptide alone · 1993

5 results

A method for evaluation of activity of antagonistic analogs of growth hormone-releasing hormone in a superfusion system.

Rekasi Z, Schally AV

Proceedings of the National Academy of Sciences of the United States of America1 Mar 1993Cited by 10 (Europe PMC)

PMID8460121 (opens in a new tab)PMCIDPMC46042 (opens in a new tab)DOI10.1073/pnas.90.6.2146 (opens in a new tab)PepBankPUB-08460121
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 01LabNot a test of Sermorelin aloneIn vitro (cells)Activity measurement

    The standard GHRH antagonist [N-Ac-Tyr1,D-Arg2]GHRH-(1-29)-NH2 had an IC50 of 4.5 x 10(-8) M in the superfusion system.

    In plain wordsIn lab tests, a GHRH blocker needed a concentration of 4.5 x 10(-8) M to cut the response by half.

    Peptide
    Sermorelin
    Outcome
    Not applicableIC50 of GHRH antagonist
    Study

    n: not reported in source

    dispersed pituitary cell superfusion system
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Measurements

    IC50
    4.5 x 10(-8) M
    standard GHRH antagonist, superfusion system

    Source sentences

    Summary
    The concentration causing 50% inhibition (IC50) of the standard GHRH antagonist human [N-Ac-Tyr1,D-Arg2]GHRH-(1-29)-NH2 is 4.5 x 10(-8) M in our dispersed pituitary cell superfusion system.
    1 context sentence
    Summary · context
    To evaluate the endocrine effect of these GHRH antagonists, a sensitive dynamic in vitro system has been developed.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 02LabNot a test of Sermorelin aloneIn vitro (cells)Mechanism

    The GHRH antagonist (10(-9) to 10(-6) M) inhibited the pulsatile GH release induced by 10(-9) M human GHRH-(1-29)-NH2, by preincubation and by simultaneous administration.

    In plain wordsIn pituitary cells, a GHRH blocker reduced GH release that GHRH had triggered.

    Peptide
    Sermorelin
    Outcome
    DecreaseInhibition of GHRH-induced pulsatile GH release
    Study

    n: not reported in source

    dispersed pituitary cell superfusion system
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    The pulsatile GH release induced by 10(-9) M human GHRH-(1-29)-NH2 was inhibited by two modes of application, preincubation and simultaneous administration of the GHRH antagonist (10(-9) to 10(-6) M).
    1 context sentence
    Summary · context
    To evaluate the endocrine effect of these GHRH antagonists, a sensitive dynamic in vitro system has been developed.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  3. 03LabNot a test of Sermorelin aloneIn vitro (cells)Mechanism

    The reduction in GHRH-stimulated GH response was more pronounced with antagonist preincubation than with simultaneous application.

    In plain wordsIn pituitary cells, adding the GHRH blocker before GHRH reduced GH release more than adding both together.

    Peptide
    Sermorelin
    Outcome
    Not applicablePreincubation versus simultaneous antagonist application
    Study

    n: not reported in source

    dispersed pituitary cell superfusion system
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    The reduction in GHRH-stimulated GH response was more pronounced when the cells were preincubated with the antagonist prior to GHRH infusion than for simultaneous application.
    1 context sentence
    Summary · context
    To evaluate the endocrine effect of these GHRH antagonists, a sensitive dynamic in vitro system has been developed.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  4. 04LabNot a test of Sermorelin aloneIn vitro (cells)Mechanism

    The inhibitory effect of the GHRH antagonist was dose-dependent, temporary and of the competitive type.

    In plain wordsIn pituitary cells, the GHRH blocker worked in a dose-dependent, temporary and competitive way.

    Peptide
    Sermorelin
    Outcome
    DecreaseDose dependence and type of antagonist inhibition
    Study

    n: not reported in source

    dispersed pituitary cell superfusion system
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    The inhibitory effect of the antagonist was dose-dependent, temporary, and of the competitive type.
    1 context sentence
    Summary · context
    To evaluate the endocrine effect of these GHRH antagonists, a sensitive dynamic in vitro system has been developed.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  5. 05LabNot a test of Sermorelin aloneIn vitro (cells)Mechanism

    GH release induced by a nonspecific stimulus (100 mM potassium chloride) was not influenced by the GHRH antagonist.

    In plain wordsIn pituitary cells, the GHRH blocker did not change GH release triggered by potassium chloride.

    Peptide
    Sermorelin
    Outcome
    No significant changeGH release induced by potassium chloride
    Study

    n: not reported in source

    dispersed pituitary cell superfusion system
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    GH release induced by nonspecific stimulus (100 mM potassium chloride) was not influenced by the GHRH antagonist.
    1 context sentence
    Summary · context
    To evaluate the endocrine effect of these GHRH antagonists, a sensitive dynamic in vitro system has been developed.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.